Founders Fund Vi Management, LLC Cyclo Therapeutics, Inc. Transaction History
Founders Fund Vi Management, LLC
- $994 Million
- Q3 2024
A detailed history of Founders Fund Vi Management, LLC transactions in Cyclo Therapeutics, Inc. stock. As of the latest transaction made, Founders Fund Vi Management, LLC holds 110,023 shares of CYTH stock, worth $63,813. This represents 18.16% of its overall portfolio holdings.
Number of Shares
110,023
Previous 110,023
-0.0%
Holding current value
$63,813
Previous $140 Million
29.13%
% of portfolio
18.16%
Previous 100.0%
Shares
1 transactions
Others Institutions Holding CYTH
# of Institutions
20Shares Held
2.25MCall Options Held
0Put Options Held
0-
Epiq Capital Group, LLC San Francisco, CA739KShares$428,8670.18% of portfolio
-
Vanguard Group Inc Valley Forge, PA599KShares$347,2420.0% of portfolio
-
Founders Fund V Management, LLC San Francisco, CA481KShares$278,8107.36% of portfolio
-
Geode Capital Management, LLC Boston, MA152KShares$88,3520.0% of portfolio
-
Black Rock Inc. New York, NY59.5KShares$34,5150.0% of portfolio
About Cyclo Therapeutics, Inc.
- Ticker CYTH
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 8,439,440
- Market Cap $4.89M
- Description
- Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of...